2021
DOI: 10.1007/978-3-030-68763-2_11
|View full text |Cite
|
Sign up to set email alerts
|

Certainty Pooling for Multiple Instance Learning

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 8 publications
0
2
0
Order By: Relevance
“…For breast cancer, a key task is understanding whether the WSI contains mitotic or non-mitotic cells, 89,[92][93][94][95][96][97][98][99][100][101][102] or tumorous cells. 103,102 Studies have explored the use of ML to distinguish breast cancer WSIs between normal, benign, carcinoma in situ (CIS) and breast invasive carcinoma (BIC).…”
Section: Classificationmentioning
confidence: 99%
See 1 more Smart Citation
“…For breast cancer, a key task is understanding whether the WSI contains mitotic or non-mitotic cells, 89,[92][93][94][95][96][97][98][99][100][101][102] or tumorous cells. 103,102 Studies have explored the use of ML to distinguish breast cancer WSIs between normal, benign, carcinoma in situ (CIS) and breast invasive carcinoma (BIC).…”
Section: Classificationmentioning
confidence: 99%
“…For breast cancer, a key task is understanding whether the WSI contains mitotic or non-mitotic cells, 89,[92][93][94][95][96][97][98][99][100][101][102] or tumorous cells. 103,102 Studies have explored the use of ML to distinguish breast cancer WSIs between normal, benign, carcinoma in situ (CIS) and breast invasive carcinoma (BIC). 104 Classification has also been used to identify specific subtypes of immunostaining for estrogen, progesterone, and Her2 receptors (ER/PR/Her2), 105,106 Ductal or Lobular, Basal-like or non-Basal-like, and different tumor grades.…”
Section: Classificationmentioning
confidence: 99%